Teva Pharmaceutical Industries Shares Outstanding 2010-2024 | TEVA
Teva Pharmaceutical Industries shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Teva Pharmaceutical Industries shares outstanding for the quarter ending June 30, 2024 were 1.133B, a 1.16% increase year-over-year.
- Teva Pharmaceutical Industries 2023 shares outstanding were 1.119B, a 0.81% increase from 2022.
- Teva Pharmaceutical Industries 2022 shares outstanding were 1.11B, a 0.27% increase from 2021.
- Teva Pharmaceutical Industries 2021 shares outstanding were 1.107B, a 1.1% increase from 2020.
Teva Pharmaceutical Industries Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
1,119 |
| 2022 |
1,110 |
| 2021 |
1,107 |
| 2020 |
1,095 |
| 2019 |
1,091 |
| 2018 |
1,021 |
| 2017 |
1,016 |
| 2016 |
961 |
| 2015 |
864 |
| 2014 |
858 |
| 2013 |
850 |
| 2012 |
873 |
| 2011 |
893 |
| 2010 |
921 |
| 2009 |
896 |
Teva Pharmaceutical Industries Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
1,133 |
| 2024-03-31 |
1,123 |
| 2023-12-31 |
1,119 |
| 2023-09-30 |
1,135 |
| 2023-06-30 |
1,120 |
| 2023-03-31 |
1,115 |
| 2022-12-31 |
1,110 |
| 2022-09-30 |
1,119 |
| 2022-06-30 |
1,110 |
| 2022-03-31 |
1,107 |
| 2021-12-31 |
1,107 |
| 2021-09-30 |
1,109 |
| 2021-06-30 |
1,109 |
| 2021-03-31 |
1,107 |
| 2020-12-31 |
1,095 |
| 2020-09-30 |
1,096 |
| 2020-06-30 |
1,100 |
| 2020-03-31 |
1,096 |
| 2019-12-31 |
1,091 |
| 2019-09-30 |
1,092 |
| 2019-06-30 |
1,092 |
| 2019-03-31 |
1,090 |
| 2018-12-31 |
1,021 |
| 2018-09-30 |
1,018 |
| 2018-06-30 |
1,018 |
| 2018-03-31 |
1,020 |
| 2017-12-31 |
1,016 |
| 2017-09-30 |
1,017 |
| 2017-06-30 |
1,017 |
| 2017-03-31 |
1,017 |
| 2016-12-31 |
961 |
| 2016-09-30 |
984 |
| 2016-06-30 |
920 |
| 2016-03-31 |
920 |
| 2015-12-31 |
864 |
| 2015-09-30 |
862 |
| 2015-06-30 |
859 |
| 2015-03-31 |
859 |
| 2014-12-31 |
858 |
| 2014-09-30 |
861 |
| 2014-06-30 |
857 |
| 2014-03-31 |
852 |
| 2013-12-31 |
850 |
| 2013-09-30 |
846 |
| 2013-06-30 |
849 |
| 2013-03-31 |
856 |
| 2012-12-31 |
873 |
| 2012-09-30 |
869 |
| 2012-06-30 |
873 |
| 2012-03-31 |
882 |
| 2011-12-31 |
893 |
| 2011-09-30 |
890 |
| 2011-06-30 |
896 |
| 2011-03-31 |
902 |
| 2010-12-31 |
921 |
| 2010-09-30 |
921 |
| 2010-06-30 |
921 |
| 2010-03-31 |
921 |
| 2009-12-31 |
900 |
| 2009-09-30 |
915 |
| 2009-06-30 |
895 |
| 2009-03-31 |
894 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.902B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
